We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Early Markers Detected For Epstein Barr Virus

By LabMedica International staff writers
Posted on 03 Dec 2012
Molecular tests that can identify early protein markers produced by Epstein Barr Virus (EBV) may have value for diagnosing active infection.

The benefits of this diagnostic approach in patients with mononucleosis and in EBV-infected transplant patients have been evaluated by comparing three different immunoassays.

Scientists at University College Dublin (Ireland) investigate the diagnostic value of anti-early antigen (EA) immunoglobulin G (IgG) testing in the stage-specific differential diagnosis of EBV infection in immunocompetent individuals with atypical antibody responses. More...
Furthermore, they assessed whether anti-EA IgG detection in conjunction with EBV DNA viral load quantification had better predictive value than EBV DNA alone in the diagnosis of EBV-associated disease in immunosuppressed adult liver transplant recipients. During the study period, none of the patients developed post-transplantation lymphoproliferative disorders (PTLD).

Eighty-five serum or plasma samples from 69 individuals were selected from the archived database. The detection of EA IgG in patients' samples was carried out using three different specific serological assays. The enzyme-linked immunosorbent assay (ELISA) is a microtiter plate assay, which detects and quantifies specific human IgG against EBV p54 EA. The Liaison chemiluminescent immunoassay (CLIA) is a two-step, immunoluminometric sandwich assay using directly coated magnetic particles for the detection of EBV EA IgG against the p54 EA. The recomBlot EBV IgG qualitative immunoblot assay was used as the gold standard. Amplification and quantification of DNA was performed using the Light Cycler EBV Quantification kit (Roche Diagnostics; Mannheim, Germany).

The results showed that the CLIA (DiaSorin; Saluggi, Italy) and immunoblot (Mikrogen; Neuried, Germany) produced more comparable results. However, there was a significant difference between the results of the ELISA (MP Biomedicals; Eschwege, Germany) and the immunoblot EA IgG assays and the results of the CLIA and ELISA assays. Comparisons with the immunoblot results showed that the CLIA is more sensitive (77%) than the ELISA (50%), but that the CLIA is less specific (42%) than the ELISA (100%).

The authors concluded that the automated CLIA was found to be more accurate than the ELISA when using the immunoblot assay as a “gold standard” assay in the detection of EA IgG. There may be a potential role for EA IgG testing, together with EBV viral load, in the prediction of transplant recipients at risk of EBV-associated disease. However, EA IgG does not play a significant role in the differential diagnosis of EBV infection in immunocompetent individuals. The study was published on November 2, 2012, in the journal BioResearch Open Access.

Related Links:

University College Dublin
Roche Diagnostics
DiaSorin



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.